SCHEMBL5506754

SCHEMBL5506754

COc1cccc(-c2[c]cccc2F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
MAOB P27338 2/20 0.43
CYP1A1 P04798 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2E1 P05181 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C8 P10632 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2A6 P11509 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP4B1 P13584 1/20 0.43
CYP2B6 P20813 1/20 0.43
CYP3A5 P20815 1/20 0.43
CYP2A7 P20853 1/20 0.43
CYP3A7 P24462 1/20 0.43
CYP2F1 P24903 1/20 0.43
CYP2C18 P33260 1/20 0.43
CYP2C19 P33261 1/20 0.43
CYP2J2 P51589 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17514939 0.86 CYP1A1 (0.46) CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8
SCHEMBL7843209 0.83 DYRK1A (0.45) DYRK1ACLK4MAOBCYP1A1CYP1A2
SCHEMBL3411791 0.83 CYP1A1 (0.45) DYRK1ACLK4MAOBCYP1A1CYP1A2
SCHEMBL9649195 0.82 AKR1C3 (0.41) DYRK1ACLK4MAOBCYP1A1CYP1A2
SCHEMBL9430884 0.82 DYRK1A (0.44) DYRK1ACLK4MAOBCYP1A1CYP1A2
SCHEMBL2377417 0.82 HDAC4 (0.55) DYRK1ACLK4CYP1A1CYP1A2CYP2E1
SCHEMBL9070549 0.80 CLK4 (0.41) DYRK1ACLK4MAOBCYP1A1CYP1A2
SCHEMBL17444071 0.79 ACHE (0.41) RPS6KA3AKR1C3AKR1C2NOTUMACHE
SCHEMBL1274110 0.79 DYRK1A (0.40) DYRK1ACLK4CYP1A1CYP1A2CYP2E1
SCHEMBL10494072 0.79 TAAR1 (0.41) CYP3A4NOTUMACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1817294-A1 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS Amgen Inc. (US) 2007-08-15 EP disclosed
WO-2006019975-A1 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS AMGEN INC. (US) 2006-02-23 WO disclosed